Compare Range Nuclear Renaissance ETF (NUKZ) vs Novo Nordisk A/S (NVO) Price & Performance

Range Nuclear Renaissance ETFTrade

Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Range Nuclear Renaissance ETF vs Novo Nordisk A/S — how do they compare? Range Nuclear Renaissance ETF trades at $66.18, while Novo Nordisk A/S trades at $44.8 (market cap $200.69B). The key difference: Novo Nordisk A/S pays a 3.98% dividend while Range Nuclear Renaissance ETF pays none. Which is the better fit depends on your goals.

	NUKZ	NVO
Sector	Sector/Thematic	Health
52-Week High	$76.23	$63.98
52-Week Low	$59.84	$35.29
Market Cap	—	$200.69B
Enterprise Value	—	$215.49B
Dividend Yield	—	3.98%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Range Nuclear Renaissance ETF

No Aura AI signal available yet.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.

NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NUKZ

View details →

NVO

Canada imposes retaliatory tariffs on $20B of U.S. goods, escalating trade tensions and impacting North American supply chains.Seeking Alpha · 2 days agoNeutral 4-Factor Dividend Growth Strategy slightly outperforms SCHD with 14.89% returns, testing new variants.Seeking Alpha · 3 days agoBullish View details →

About Range Nuclear Renaissance ETF

Range Nuclear Renaissance ETF seeks to track companies related to the nuclear energy industry. Its holdings may include businesses involved in uranium, nuclear power generation, reactors, and nuclear services.

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.